Skip to content
Screener

Jazz Pharmaceuticals JAZZ Q4 2025 Annual earnings

Reported February 24, 2026 · After market close

Revenue$1.2BBeat by $32.7M
EPS$6.64Beat by $0.12
Revenue estimate$1.2B
EPS estimate$6.52

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$1.2B
EPS estimate$6.47

Financials

Q4 2025

Income statement

See full
Revenue$1.2B+10.1%

Balance sheet

See full
Cash & equivalents$682.7M-71.7%
Total debt$5.4B-12.0%
Total equity$4.3B+5.5%
Total assets$11.7B-2.9%

Cash flow

See full
Operating cash flow$362.5M-9.0%
CapEx$16.7M+25.9%
Free cash flow$345.8M-10.3%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$10.33B+38.8%
Enterprise value$15.07B+34.6%
P/S2.4×+0.6×

Profitability

See full
FCF margin30.4%-3.0pp

Returns & leverage

See full
Debt / equity1.3×-0.2×
Current ratio1.9×-2.6×

Segments

By product

See full
Xywav$465.5M+16.1%
Epidiolex/Epidyolex$287.1M+4.4%
Rylaze/Enrylaze$108.2M+6.6%
Zepzelca$90.4M+15.5%
Defitelio/defibrotide$58.9M+2.1%

By geography

See full
Europe$88.9M+8.6%
All other$32.7M+0.1%

FAQ

When did Jazz Pharmaceuticals report Q4 2025 earnings?
Jazz Pharmaceuticals (JAZZ) reported Q4 2025 earnings on February 24, 2026 after market close.
What were Jazz Pharmaceuticals's Q4 2025 revenue and EPS?
Jazz Pharmaceuticals reported revenue of $1.2B and eps of $6.64 for Q4 2025.
Did Jazz Pharmaceuticals beat estimates in Q4 2025?
Revenue beat the consensus estimate of $1.2B by $32.7M. EPS beat the consensus estimate of $6.52 by $0.12.
How did Jazz Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 10.1% from $1.1B a year earlier and eps grew 0.6% from $6.60.
Where can I find Jazz Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001232524-26-000012) and the 10-K periodic report (0001232524-26-000013) directly on SEC EDGAR. The filing index links above go to sec.gov.